CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03001544
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:20.440997+00:00
Published At: 2016-12-23T00:00:00+00:00
Record Updated At: 2016-12-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Thrombosis", "Cerebral Ischemia", "Venous Thrombosis", "Pulmonary Embolism", "Myocardial Infarction"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-12-23"
protocolSection.identificationModule.nctId: "NCT03001544"
protocolSection.identificationModule.officialTitle: "Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (\u03b12AP) Monoclonal Antibody TS23 in Healthy Human Volunteers"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.